Invesco Ltd. Neurocrine Biosciences Inc Transaction History
Invesco Ltd.
- $453 Billion
- Q1 2024
A detailed history of Invesco Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Invesco Ltd. holds 1,136,942 shares of NBIX stock, worth $157 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,136,942
Previous 673,808
68.73%
Holding current value
$157 Million
Previous $88.8 Million
76.62%
% of portfolio
0.03%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.9 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.37 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$552 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$317 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$311 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...